Carisma Therapeutics (CARM) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Carisma Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights Initial data for CT-0525, lead product candidate for anti-HER2 program, expected by year-end 2024 Nomination of a development candidate for liver fibrosis program expected in the first quarter of 2025 Nominated first in vivo CAR-M development candidate targeting Glypican-3 to treat hepatocellular carcinoma under the Moderna Collaboration in the second quarter of 2024 Cash and cash equivalents of $4 ...